Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
How Much Upside is Left in Catalyst (CPRX)? Wall Street Analysts Think 43.34%
10:55am, Friday, 06'th Mar 2026
The consensus price target hints at a 43.3% upside potential for Catalyst (CPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and
All You Need to Know About Catalyst (CPRX) Rating Upgrade to Strong Buy
01:01pm, Wednesday, 04'th Mar 2026
Catalyst (CPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stock to Buy for March 4th
11:01am, Wednesday, 04'th Mar 2026
BTSG, XP and CPRX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 4, 2026.
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now?
10:41am, Wednesday, 04'th Mar 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Best Value Stocks to Buy for March 4th
10:06am, Wednesday, 04'th Mar 2026
CPRX and XP made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 4, 2026.
New Strong Buy Stocks for March 4th
06:11am, Wednesday, 04'th Mar 2026
ORN, LRCX, GMED, MYRG and CPRX have been added to the Zacks Rank #1 (Strong Buy) List on March 4, 2026.
Catalyst Pharmaceuticals Q4 Earnings Call Highlights
04:50am, Sunday, 01'st Mar 2026
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported fourth-quarter and full-year 2025 results that management said reflected continued revenue growth across its commercial portfolio, led by Firdapse and
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2025 Earnings Call Transcript
03:27pm, Thursday, 26'th Feb 2026
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2025 Earnings Call Transcript
Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y
11:11am, Thursday, 26'th Feb 2026
CPRX tops Q4 estimates as Firdapse and Agamree sales jump, lifting 2025 results and driving upbeat 2026 revenue guidance.
Catalyst (CPRX) Reports Q4 Earnings: What Key Metrics Have to Say
10:31am, Thursday, 26'th Feb 2026
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street esti
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
04:07pm, Wednesday, 25'th Feb 2026
Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FI
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
10:50am, Tuesday, 24'th Feb 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Ahead of Catalyst (CPRX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
10:15am, Tuesday, 24'th Feb 2026
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Catalyst (CPRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qu
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
08:03am, Tuesday, 24'th Feb 2026
CORAL GABLES, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
